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Platelet-derived growth factor (PDGF) has been shown to be essential in the activation of hepatic stellate cells (HSCs), contributing to the onset
and development of hepatic fibrosis. Recently, sphingosine-1-phosphate (S1P) has been shown to be a mitogen and stimulator of chemotaxis also
for HSCs. Since it has been demonstrated in several cell types that cross-talk between PDGF and S1P signalling pathways occurs, our aim was to
investigate the potential antifibrotic effect of FTY720, whose phosphorylated form acts as a potent S1P receptor (S1PR) modulator, on HSCs.
FTY720 inhibits cell proliferation and migration after PDGF stimulation on HSCs in a concentration range between 0.1 and 1 μM. By using
compounds that block S1P signalling (PTX and VPC23019), we assessed that FTY720 also acts in an S1P receptor-independent way by
decreasing the level of tyrosine phosphorylation of PDGF receptor, with subsequent inhibition of the PDGF signalling pathway. In addition,
inhibition of sphingosine kinase2 (SphK2), which is responsible for FTY720 phosphorylation, by DMS/siRNA unveils a mechanism of action
irrespective of its phosphorylation, in particular decreasing the level of S1P1 on the plasma membrane. These findings led us to hypothesize a
potential use of FTY720 as a potential antifibrotic drug for further clinical application.
© 2007 Elsevier B.V. All rights reserved.Keywords: Integrative signalling; S1P receptor; PDGF receptor; PTX1. Introduction
Liver fibrosis is a dynamic, regulated wound-healing process
in response to chronic liver injury and is characterised by the
accumulation of extracellular matrix (ECM) proteins, most
commonly fibrillar collagen, types I and III [1,2]. In brief, liver
injury results in the recruitment and stimulation of inflammatory
cells, which release factors causing transformation of hepatic⁎ Corresponding author. Tel.: +39 0498212210 11; fax: +39 049 656145.
E-mail address: enrico.gringeri@unipd.it (E. Gringeri).
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doi:10.1016/j.bbamcr.2007.11.008stellate cells (HSCs) into a myofibroblast-like phenotype,
acquiring contractile, pro-inflammatory and fibrogenic proper-
ties [3,4] and, in particular, leading to increased deposition of
scar (fibrillar) ECM. The presence of a fibrillar ECM in the Disse
space, where HSCs normally reside, in turn contributes to the
loss of microvilli and endothelial fenestrae, and thus to the loss
of normal tissue architecture and impairment of organ function
[5,6].
HSC activation during fibrogenesis reflects the activity of
several soluble factors, including growth factors, cytokines,
chemokines and their cognate receptors. Among these, the
most potent mitogen and effective chemotactic factor for
HSCs is the platelet-derived growth factor (PDGF) [7,8,9], the
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reported to be increased in both experimental rat and human
models of liver fibrosis [10], suggesting that the PDGF
signalling pathway may provide novel therapeutic targets for
antifibrotic therapy in liver diseases.
PDGFR, as other growth factor receptor tyrosine kinases,
can be trans-activated by sphingosine-1-phosphate (S1P), a
pleiotropic lipid mediator of many biological processes,
produced by phosphorylation of sphingosine by two sphin-
gosine kinase isoenzymes (SphK1 and SphK2). S1P acts as
both an intracellular second messenger, stimulating cell
proliferation and inhibiting apoptosis, and an extracellular
modulator, regulating a number of functions, such as
cytoskeletal rearrangements and cell movement, angiogenesis
and vascular maturation, immunity and lymphocyte traffick-
ing. The latter role is mediated by its binding to a family of
five cognate G protein-coupled receptors (S1PRs), designated
S1P1–5 [11,12].
In particular, S1P binding to S1P1 results in the above-
mentioned trans-activation of growth factor receptors, through
diverse mechanisms which are not mutually exclusive,
including:
(1) intracellular cross-talk between receptors and direct
phosphorylation of receptor tyrosine kinases (RTKs) by
protein tyrosine kinases [13,14];
(2) induced expression and/or secretion of growth factors
[15];
(3) involvement of S1P1 and RTKs in a signalplex by either
direct interaction with receptors or binding of both
receptors to scaffolding proteins [16,17]. Conversely,
the binding of PDGF to its receptor causes SphK1
translocation and activation, leading to the spatially
restricted formation of S1P which, in turn, further
activates S1PR “inside-out signalling” [18,19].
S1P has recently been shown to increase the proliferation of
cultured activated HSCs via the pertussis toxin (PTX)-sensitive
pathway and HSC contractile properties by Rho pathway
activation [20,21].
The main aim of this work is to investigate the interplay
between PDGFR and S1P1, especially with respect to HSC
activation and the potential antifibrotic effect of agents capable
of interfering with these signalling pathways. In fact, although
the role of S1P and its receptors has already been studied
extensively, little is yet known about the role of S1P in
hepatic-derived cells, either in normal or damaged liver. In this
regard, recent works have reported that FTY720, a novel
immunosuppressant [22], can exert its effects on the S1P
pathway.
FTY720 is structurally a derivative of myriocin, a prominent
metabolite of the fungus Isaria sinclairii, sharing close
structural similarity to S1P. It is a compound effective in
prolonging allograft survival of heart, kidney and liver in animal
models, and currently used as an immunomodulator in Phase III
trials for patients with multiple sclerosis or undergoing renal
transplantation [23,24]. It is considered to be a potent agonistfor four of the five currently known S1P receptors (S1P1 and
S1P3–S1P5) after being phosphorylated (FTY720-P) by SphK2.
It has been reported that FTY720-P binding to S1P1 on
lymphocytes prevents their egress from secondary lymphoid
organs, thus reversibly sequestering them from sites of
inflammation. However, the mechanism of action of FTY720-
P on S1P receptors is still controversial: FTY720-P may prevent
lymphocyte egress via S1P1 by acting as a direct agonist;
another model suggests that FTY720 inactivates S1P1 on
lymphocytes as a ‘functional antagonist’ and induces lympho-
cyte-specific S1P1 down-regulation[25–28]. The finding that
FTY720 may induce receptor internalisation and subsequent
degradation, supports the hypothesis of S1P1-inactivation by
FTY720 [29].
Our results provide clear evidence that FTY720, after PDGF-
BB activation, is able to inhibit the proliferation andmigration of
cultured activated HSCs in a S1PR-dependent and independent
way.
2. Materials and methods
2.1. Materials and chemicals
Unless otherwise specified, reagents were obtained from Sigma (St.Louis,
MO). OPTIMEM medium, Stealth™ RNAi for SphK2, Stealth™ RNAi
Negative Control Duplexes, Lipofectamine™ 2000 Transfection Reagents were
purchased from Invitrogen. VPC23019, N,N-Dimethyl-D-erythro-Sphingosine
(DMS) Avanti Polar Lipids (Alabaster, AL). FTY720 was kindly provided by
Novartis. DELFIA Cell proliferation kit was provided by Perkin Elmer, Inc.
Antibodies were obtained as follows: anti-S1P1 (Cayman Chemical Co., Ann
Arbor, MI.), anti-PDGFR-β, anti-SphK2 and S1P2 (Santa Cruz Biotechnology
Inc., Santa Cruz, CA); anti-P-ERK1/2, anti-ERK, anti-P-Akt, anti-Akt (Cell
Signaling Technology, Inc), anti-phosphotyrosine (PY-20) monoclonal antibody
(MBP). Anti-GAPDH antibody was purchased from Sigma-Aldrich Inc. (Saint
Louis, MO). [γ-32P]ATP and enhanced chemiluminescent detection system
(ECL) were purchased from Amersham Pharmacia Biotech. Protease inhibitor
cocktail was purchased from Roche Diagnostics.
2.2. Cell isolation and culture
Hepatic stellate cells were isolated from normal male Winstar rats. All
animals were purchased from Charles River Laboratories and were housed in the
Animal research Facility of Biological-Chemistry Department, in accordance
with the National Institute of Health guidelines for the care of Laboratory
animals. They were maintained under a 12-hour light–dark cycle and given rat
chow and water ad libitum.
HSCs were isolated from normal livers according to a modified Zhang
method [30]; livers were perfused with a calcium-free buffer solution to wash
out the blood, subsequently with a wash solution (calcium-free solution with
CaCl2 0.294 g/L, MgSO4 0.097 g/L) and finally incubated in a digestion
buffer (collagenase 0.6 g/L in Gey's Balanced Salt Solution with Ca2+and
Mg2+, pH 7.5) for 1 h (37 °C, CO2 5%) to digest the extracellular matrix. The
organs were cut into small pieces and subjected to homogenization to produce
a single cell-suspension, which was centrifuged at 1450 ×g for 18 min in 12%
(wt/vol) Nycodenz gradient to obtain a pure HSC fraction. Both the number
and viability of HSCs were determined using the trypan blue dye exclusion
test.
Collected HSCs were washed with Hank's balanced salt solution and
resuspended at a concentration of 1×105 cells/ml, in Dulbecco's modified
Eagle's medium (DMEM) [supplemented with 20% fetal bovine serum (FBS)
and 1× antibiotic solution] and cultured on collagen type I coated well plates
(10 μg/ml) in a 5% CO2-humidified atmosphere. Serum-starved cells were
subsequently detached for experiments using trypsin/EDTA solution.
All cell experiments were performed between passages 3 and 8.
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DNA synthesis was determined as the amount of 5-bromo-2′-deoxyuridine
(BrdU) incorporated into newly synthesized DNA strand of proliferating cells.
HSCs were seeded on 96-well plates at a density of 15×103, incubated in
OPTIMEM medium for 24 h to stop cell growth and stimulated for further 24 h
with PDGF (10 ng/ml), alone or in the presence of increasing concentrations of
S1P (0.1, 0.5, 1, 3 μM), and of FTY720 (0.1, 0.3, 0.5, 1 μM). Alternatively cells
were preincubated with pertussis toxin (PTX) (100 ng/ml) for 16 h, with
VPC23019 (1 μM) for 1 h, or with DMS (10 μM) for 30 min and then treated
with PDGF-BB (10 ng/ml) alone or in the presence of S1P (1 μM) or FTY720
(1 μM) for 24 h.
During the last 4 h of incubation, BrdU (10 μM) was added to each well.
After removal of supernatant, the cells were fixed and then incubated with anti-
BrdU antibody conjugated to Europium (anti-BrdU-Eu). Bound anti-BrdU-Eu
was measured by fluorescence emission analysis (Victor3 1420 multilabel
Counter PerkinElmer Life Science) as suggested by the manufacturer (DELFIA
Cell proliferation kit).
2.4. Cell proliferation assay
HSCs were plated on 24-well dishes at a density of 25×103 and incubated in
OPTIMEM medium alone for 24 h. Cells were then stimulated with PDGF-BB
(10 ng/ml) in the presence or absence of increasing concentrations of FTY720
for different time periods and counted. Cell count was performed on triplicate
wells on day 0 and after 2 and 4 days. At each time point cells were trypsinizedFig. 1. Effect of S1P and FTY720 on cell proliferation in HSCs. (A) Effect of increasin
DNA, in HSC cells in the absence or presence of PDGF-BB (10 ng/ml). Data are
concentrations of FTY720 on DNA synthesis, evaluated as BrdU incorporation into D
mean±SD for 4 experiments performed in triplicate. Compared with the effect of PDG
significance) starting at 0.1 μM of FTY720 (C) Effect of increasing concentrations o
25×103 in OPTIMEM medium. After 24 h (day 0), cells were washed and incubated
without increasing doses of FTY720. At each time point cells were trypsinized and co
same test conditions was added on day 2. Data are mean±SD for 2 experiments perf
concentrations of FTY720 tested. (D) Cytotoxic effect of FTY720 on HSCs. Cells we
48 h and subjected to MTTassay (left panel) or trypan blue dye exclusion test (right pa
not statistically significant.and counted in a Fuchs–Rosenthal counting chamber. Fresh medium containing
the same test conditions was added on day 2 to the remaining wells.
2.5. Cell viability assay
HSCs were seeded on 96-well plates, incubated in OPTIMEM medium for
24 h to stop cell growth, and exposed to increasing concentrations of FTY720
(in OPTIMEM medium) for 48 h.
HSCs were subsequently washed and treated with 300 μl 1-(4,5-
Dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) (0.5 mg/ml) for 3 h at
37 °C. Absorbance was measured at 540 nm in a multiscan spectrophotometer.
2.6. Cell death assay
Confluent HSCs were incubated in OPTIMEM medium for 24 h and
exposed to increasing concentrations of FTY720 (0.1, 0.3, 0.5 and 1 μM). Cell
viability was evaluated by the trypan blue dye exclusion test at the end of a 48-
hour incubation period. The number of cells excluding trypan blue or stained
with trypan blue were counted under a light microscope. The percentage of cells
excluding trypan blue was used as an index of cell viability.
2.7. Western blot analysis
Cells were seeded on 6-well plates, cultured in DMEM medium up to
confluence and then incubated for 24 h in OPTIMEM medium. Cultured cells
were subjected to various stimuli, as described in figure legends, detached byg concentrations of S1P on DNA synthesis, evaluated as BrdU incorporation into
mean±SD for 4 experiments performed in triplicate (B) Effect of increasing
NA, in HSC cells in the absence or presence of PDGF-BB(10 ng/ml). Data are
F-BB alone, changes were statistically significant (∗Pb0.05 or higher degree of
f FTY720 on HSC number. HSCs were plated on 24-well dishes at a density of
in fresh OPTIMEM medium alone (control) or with PDGF (10 ng/ml), with or
unted with a Fuchs–Rosenthal counting chamber. Fresh medium containing the
ormed in triplicate. Changes were statistically significant starting at day 2 for all
re incubated with different concentration of FTY720 in OPTIMEM medium for
nel). Data are mean±SD for 4 experiments performed in triplicate. Changes were
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quickly lysed in a buffer containing 62 mM Tris–HCl solution (pH 6.8), 5%
glycerol, 0.5% SDS, and 0.5% β-mercaptoethanol. Samples were run in 10%
SDS-PAGE and transferred to nitrocellulose membranes. After treatment with
3% bovine serum albumin at 4 ° C overnight, membranes were incubated withFig. 2. Effect of PTX, VPC23019, DMS and FTY720 on HSC proliferation. (A) HSCs
for 16 h, or with VPC23019 (1 μM) for 1 h, followed by stimulation with PDGF-BB
(1 μM) in the presence of PDGF, respectively, for 24 h. Compared with the effect of P
due to pretreatment with PTX or VPC23019, were statistically significant (Pb0.05 or h
in statistically significant changes compared to control treatedwith FTY720 in associat
VPC23019 (1 μM) for 1 h and subsequently incubatedwith increasing concentrations o
30 min and subsequently for 24 h with PDGF (10 ng/ml) alone or in the presence of FT
with PDGF-BB, changes due to pretreatment with DMS were statistically significan
difference between HSCs treated with DMS and PDGF-BB alone or in the presence o
BrdUwas added to cultures to evaluate DNA synthesis, as described in the sectionMathe appropriate antibodies for 2 h and, after washing, with secondary horseradish
peroxidase-conjugated polyclonal antibody for 1 h. Bound antibodies were
detected by the ECL detection system (Amersham, Arlington Heights, IL) on a
Kodak Image Station 440CF and visualized with Kodak 1D Image software
(Rochester, NY).were incubated for 24 h in OPTIMEMmedium, pretreated with PTX (100 ng/ml)
(10 ng/ml), S1P (1 μM), S1P (1 μM) in association with PDGF-BB, or FTY720
DGF-BB, S1P, S1P in association with PDGF-BB, all considered alone, changes,
igher degree of significance); pretreatment with PTX or VPC23019 did not result
ionwith PDGF-BB alone. (B) HSCswere pretreatedwith FTY720 (1 μM) or with
f S1P (1, 2.5 and 5 μM) for 24 h. (C) Cells were pretreatedwith DMS (10 μM) for
Y720 (1 μM). Compared with the effect of PDGF-BB or FTY720 in association
t (Pb0.05 or higher degree of significance); also statistically significant was the
f FTY720. 20 h after each treatment (conditions used are indicated above graphs)
terials andmethods. Data are mean±SD for 4 experiments performed in triplicate.
Fig. 3. Effect of SphK2 siRNA onHSC proliferation. Cells were transfected with
scramble siRNAor SphK2 siRNA for 48 h followed by treatment with PDGF-BB
(lanes 2 and 4) for 24 h. (A) Cell lysates were subjected to Western blot analysis
for SphK2 (upper panel) and tested for SphK2 activity on FTY720 (lower panel),
as described in Materials and methods. Lanes 1 and 2: scramble siRNA; lanes 3
and 4: SphK2 siRNA. Immunoblot and TLC autoradiogram shown are
representative of 3 independent experiments. (B) Effect of FTY720 on DNA
synthesis, evaluated as BrdU incorporation, in HSCs transfected with scramble
siRNA or SphK2 siRNA for 48 h, and subsequently treated with PDGF-BB
(10 ng/ml) alone or in the presence of FTY720 (1 μM) for 24 h. Data are mean±
SD for 3 experiments performed in triplicate. Compared with the effect of
PDGF-BB or FTY720 in association with PDGF-BB, changes due to SphK2
siRNAwere statistically significant (Pb0.05 or higher degree of significance).
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after stripping with 0.1 M glycine (pH 2.5), 0.5 M NaCl, 0.1% Tween 20, 1% β-
mercaptoethanol and 0.1% NaN3 for 2×10 min.
2.8. Subcellular fractionation of HSC cells
Subcellular fractionation was performed by using OptiPrep® Density
Gradient Medium and ultracentrifugation as described elsewhere [31]. A
discontinuous gradient was prepared using 30, 25, 20, 15 and 10% OptiPrep
solved in 50 mM Tris–HCl (pH 7.5) containing a protease inhibitor cocktail.
About 6×106 cells were incubated with different stimuli, as indicated in figure
legends, were sonicated in 1 ml isotonic buffer containing 50 mM Tris–HCl (pH
7.5), 0.25 M saccharose, 1 mM orthovanadate and protease inhibitor cocktail.
Cellular debris and nuclei were pelleted by centrifugation at 1000×g for 10 min.
The supernatant was then centrifuged at 105,000×g for 1 h to separate the cytosol
from the particulate fraction. The particulate fraction, resuspended in 200 μl of
buffer [20 mM Tris–HCl (pH 7.5); 10% glycerol; 1 mM EDTA; 150 mM NaCl;
1 mM sodium orthovanadate and protease inhibitor cocktail], was overlaid onto a
discontinuous gradient of iodixanol and centrifuged at 100,000×g for 3 h at 4 ° C.
The gradient was finally divided into 15 equal aliquots collected from its top and
50 μl of them were subjected to Western Blot analysis by immunostaining with
anti-S1P1 and S1P2 antibodies and with the following organelle-specific
antibodies: anti-PMCA (plasma membrane), anti-Golgi 58K protein (Golgi
apparatus), anti-calreticulin (ER) and anti-Complex II (mitochondria).
2.9. Wound-healing assay
To measure cellular migration during wound-healing, HSCs from rats were
seeded on 24-well plates previously coated with type I collagen and grown to
confluence in DMEM medium containing 20% FBS. Confluent cells were
incubated in OPTIMEM medium for 24 h before starting the experiment.
Monolayers were then disrupted to generate a linear wound of 1 mm with a 1 ml
pipette tip, washed to remove debris and stimulated for 24 h with PDGF (10 ng/
ml) alone or in association with increasing concentrations of FTY720. Cells
were subsequently photographed by phase contrast microscopy. For all
experiments, 5 randomly selected points along each wound were marked for
the evaluation of wound closure; the distance of cell migration from the initial
condition was measured 24 h after wounding [32].
2.10. Chemotactic assay
Modified Boyden chambers equipped with 8-μm-porosity polyvinylpyrro-
lidone-free polycarbonate filters were used after precoating with type I Collagen
(10 μg/ml). Confluent HSCs were incubated in OPTIMEMmedium for 24 h and
then treated with the agonist to be tested: cells were preincubated with PTX
(100 ng/ml) for 16 h, VPC23019 (1 μM) for 1 h or with DMS (10 μM) for 30 min
and then treated with PDGF, alone or in the presence of FTY720 (1 μM) for 24 h.
After detachment, 40×103 cells were added to the top chamber and incubated
at 37 °C for 6 h. The lower chamber was filled with OPTIMEM medium in the
absence (control) or presence of PDGF, alone or in association with the agonist
used during the preincubation period. Filters were fixed with 96% methanol and
stained with Harris' hematoxylin solution [33]. Migrated cells were quantified as
a mean of ±SD in 10 randomly chosen high-power fields.
2.11. Immunoprecipitation
HSC cells were cultured, as described above, with or without PDGF (10 ng/
ml) and/or FTY720. After stimulation, 2×106 cells were suspended for 1 h at 4 °C
in 0.5 ml of buffer A (20 mM Tris–HCl, pH 7.4; 10% glycerol, 1 mM β-
mercaptoethanol, 1 mM EDTA, 15 mMNaF, 40 mM β-glycerophosphate, 1 mM
sodium orthovanadate, protease inhibitor cocktail and 0.5 mM 4-deoxypyridox-
ine) containing 1% Triton X-100. After centrifugation, equal aliquots of
supernatants were further supplemented with 0.5 ml of buffer A, without Triton
X-100. Immunoprecipitation was performed overnight in the presence of anti-
PDGFR or anti-S1P1antibodies; immunocomplexes were washed three times in
50 mM Tris–HCl (pH 7.5), 1 mM orthovanadate and protease inhibitor cocktail
and subjected to Western Blot analysis by immunostaining with anti-phosphotyrosine (PY-20) monoclonal antibody, anti-PDGFR antibody and
anti-S1P1 antibody.
2.12. RNA interference
The siRNA sequence targeting specifically rat SphK2 containing 25-nt and
corresponding to nucleotides 843–867 (AccessionNumberNM001012066)was
synthesized and annealed by Invitrogen. The two sequences used are: 5′-GGCA-
GUUAACCAUCAUGGCGGGUUU-3′ and 5′-AAACCCGCCAUGAUGGU-
UAACUGCC-3′. The day before transfection, cells were diluted with fresh
medium without antibiotics and transferred to 6-well plates (∼40% confluent).
HSC transient transfection of siRNA (40 nM) was performed by using
Lipofectamine 2000 as recommended by the manufacturer. Control cells were
treated with 40 nM RNAi Negative Control Duplexes (scramble siRNA). After
48 h cells were treated with PDGF and assayed as described.
2.13. SphK2 activity assay
SphK activity was measured using 10 μg of cellular lysates (cells were
lysated in buffer A by two freeze/thaw cycles) with 20 μM FTY720
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10 μCi of [γ-32P]ATP as substrates in a buffer containing 50 mM Hepes,
pH 7.4, 15 mM MgCl2, 0.005% Triton X-100, 1 M KCl, 10% glycerol,
10 mM NaF, and 1.5 mM semicarbazide. Incubations were carried out for
30 min at 30 °C [34]. Radiolabeled S1P and FTY720-P were separated by
60 thin-layer chromatography (TLC) on silica gel G60-plates with
choloroform/acetone/methanol/acetic acid/water (10:4:3:2:1, v/v) as solvent
and phosphate incorporation was visualized and quantified using a
PhosphorImager [35].
2.14. Statistical analysis
The bands from immunoblot were quantified by densitometric analysis.
Data are presented as mean±SD and compared using one-way analysis of
variance (ANOVA) followed by Bonferroni post hoc test or Student's t test. A
Pb0.05 was considered as statistically significant. All statistics were performed
using GraphPad Prism (version 4) statistical software (GraphPad Software; San
Diego, CA).Fig. 4. Expression of S1P1 and S1P2 in HSCs and subcellular localization of S1P1 in H
1 day (lane 1), 8 days (lane 2), third passage (lanes 3–6). Cells on the third passage we
and FTY720 (1 μM, lane 6) and to Western blot analysis with anti S1P1/2 antibodies.
represents the values of a densitometric analysis (arbitrary units) of S1P1 and S1P2 ban
as loading control. The figure represents four separate experiments. HSCs were pre
30 min, and cultured for 24 h in the absence (B, D) or in the presence (C, E) of FTY7
separated from the particulate fractions. The particulate fractions were then fractionate
organelles as described in the section Material and Methods. Aliquots of the resulting
anti-PMCA (plasma membrane), anti-Golgi 58K protein (Golgi apparatus), anti
immunoblotted with anti-S1P1 antibody. The bar graph represents the values of a den
figure represents four separate experiments.3. Results
3.1. FTY720 reduces PDGF-induced cell proliferation in
primary cultured HSCs
Previous studies have already demonstrated that S1P
increases the proliferation of culture-activated HSCs in a
PTX-sensitive way, but not in the early phase of cell culture
[20].
To investigate the potential interplay between PDGF- and
S1P-activated pathways in HSCs, we evaluated the effect of
increasing concentrations of S1P on PDGF-induced DNA
synthesis, measured as BrdU incorporation. Fig. 1A shows
the mitogenic effect of S1P, which appears to be partially
accumulative on that resulting from PDGF stimulation.SCs treated or not with FTY720. (A) HSCs grown in proliferation medium after
re subjected to different stimuli, i.e., PDGF (10 ng/ml, lane 4), S1P (1 μM, lane 5)
The molecular mass markers are displayed between the two blots. The bar graph
ds expressed as mean±SD. The blots were reprobed with anti-GADPH antibody
incubated in the absence (B, C) or in the presence (D, E) of DMS (10 μM) for
20 (1 μM). Cells were sonicated in isotonic buffer, and nuclei and cytosol were
d by centrifugation on discontinuous OptiPrep™ gradient to separate the cellular
fractions were immunoblotted with the following organelle-specific antibodies:
-calreticulin (ER) and anti-Complex II (mitochondria). Other aliquots were
sitometric analysis (arbitrary units) of S1P1 bands expressed as mean±SD. The
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to sphingosine kinase (SphK) activation and recruitment to the
plasma membrane with subsequent spatially and temporally
localized formation of S1P, which initiates the signallingFig. 5. FTY720 inhibits HSCs migration induced by PDGF. (A) Wound-healing assay
ml) and grown to confluence in DMEMmedium plus 20% FBS, incubated in OPTIME
a 1 ml pipette tip, washed to remove debris and incubated with increasing concentra
were photographed immediately by phase contrast microscopy after washing to record
24 h of incubation. A representative of three experiments are shown. (B) Cell migrat
methods. HSCs, preincubated with PTX or VPC23019 (left panel) or with DMS (righ
were trypsinized and 40×103 cells were added to the upper compartment of a modifie
precoated with collagen type I. Cells migrated to the lower surface of the filter w
observations. Compared with the effect of PDGF-BB, changes due to pretreatment w
degree of significance). Compared with the effect of PDGF-BB in association with FT
significant, while pretreatment with DMS determined statistically significant results (P
in HSCs transfected with control siRNA or SphK2 siRNA for 48 h, and subsequently
24 h. Data are mean±SD for 3 experiments performed in triplicate. Compared with th
siRNA were statistically significant (Pb0.05 or higher degree of significance).pathway through S1PRs. S1P binding to the S1PRs can also
increase PDGF production, leading to trans-activation of the
growth factor receptor which in turn activates downstream
signals capable of regulating cell proliferation and movement. 20×103 cells were seeded on 24-wells plates coated with collagen type I (20 μg/
Mmedium for 24 h. Monolayers were disrupted to generate a linear wound with
tions of FTY720 in the absence or presence of PDGF (10 ng/ml) for 24 h. Cells
the wound width. Plates were photographed at the marked wound location after
ion was determined in modified Boyden chambers as described in Materials and
t panel) and then treated with PDGF, alone or in the presence of FTY720 for 24 h
d Boyden chamber and tested for migration in the lower chamber through a filter
ere stained and quantified by cell counting. Values are the mean±SD of four
ith PTX, VPC23019 or DMS, were statistically significant (Pb0.05 or higher
Y720, changes, due to pretreatment with PTX, VPC23019, were not statistically
b0.05 or higher degree of significance). (C) Effect of FTY720 on cell migration
treated with PDGF-BB (10 ng/ml) alone or in the presence of FTY720 (1 μM) for
e effect of PDGF-BB alone or in the presence of FTY720, changes due to SphK2
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represent a new antifibrotic strategy.
Treatment with FTY720, a synthetic myriocin analogue
structurally similar to sphingosine, results in significant
inhibition of PDGF-induced DNA synthesis in a concentra-
tion-dependent manner (Fig. 1B). Growth curves of PDGF-
activated rat HSCs in the presence or absence of FTY720 were
analyzed to assess whether the decrease in PDGF-induced DNA
synthesis was associated with an actual decrease in cell growth.
The results shown in Fig. 1C confirm the significant increase in
HSC growth after PDGF-BB (10 ng/ml) stimulation after 2–
4 days' incubation, when compared with unstimulated control
cells. This effect was clearly antagonised by FTY720 treatment
and proved to be statistically significant even after 2 days'
culture. Toxic effects and cell death caused by FTY720
treatment in these experimental conditions were ruled out atall the concentrations of the compound tested by measuring the
viability and cell death in cells maintained for 48 h in serum-free
medium (Fig. 1D).
To investigate how FTY720 inhibits PDGF-induced HSC
proliferation, we used two compounds affecting different steps
of the S1P signalling pathway: pertussis toxin (PTX) [37], a Gi
protein-coupled receptor inhibitor, and VPC23019, a competi-
tive antagonist at S1PRs [38].
Pretreatment with 100 ng/ml PTX and 1 μM VPC23019
significantly decreased the mitogenic effect not only of S1P but
also of PDGF-BB on cultured activated HSCs (Fig. 2A). PTX
and VPC23019 drastically decreased the proliferative effect of
S1P, confirming that its activity is receptor-mediated and that
the applied concentrations of the two inhibitors were highly
effective in blocking S1P signalling. The reduced proliferative
activity of PDGF in the presence of PTX supports the
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coupled receptor, whereas the inhibitory effect of VPC23019
underlines the involvement of S1PRs, particularly S1P1 or S1P3.
The major inhibitory effect exerted by FTY720 on cell
proliferation, after PDGF stimulation, suggests that the
compound may act not only in a receptor-mediated manner
but also through a mechanism alternative to the S1P pathway
(Fig. 2A).
In addition, cell pretreatment with FTY720 or VPC23019
reduced the S1P mitogenic effect. This effect was counteracted
by increasing the S1P concentration in the presence of
VPC23019 but not of FTY720, suggesting that these compounds
may act by diverse mechanisms (Fig. 2B).
Pretreatment with 10 μM N,N-dimethylsphingosine (DMS),
a sphingosine kinase inhibitor [39], resulted in the inhibition of
the proliferative action mediated by PDGF, quite similar to that
induced by PTX and VPC23019 (Fig. 2C). DMS, at a
concentration that totally inhibited SphKs, partially removed
the inhibitory activity of FTY720, supporting the concept that
phosphorylated FTY720 may not be the only active form of the
compound.
This hypothesis appears to be corroborated by the findings
observed after siRNA to SphK2, which is responsible for
FTY720 phosphorylation [34] and reported to be the more
common isoform of SphK in the liver [40,41], conducted on
HSCs stimulated by PDGF. This procedure brought about the
down-regulation of SphK2 (Fig. 3A, upper panel) and nearly
total inhibition of FTY720 phosphorylation (Fig. 3A, lower
panel). Notably, PDGF treatment resulted in increase in
FTY720 phosphorylation in control siRNA treated HSCs
(Fig. 3A, lower panel, lanes 1 and 2), and this effect occurred
independently of changes in the levels of SphK2 expression, as
revealed by Western blot (Fig. 3A, upper panel, lanes 1 and 2).
Moreover, as shown in Fig. 3B, the effect of FTY720 does not
appear to be completely accounted for by phosphorylation, as
emerged from the partial reversal of its effect by SphK2 down-
regulation.Fig. 6. FTY720 decreases PDGF-β receptor tyrosine phosphorylation and ERK1/2 a
VPC23019 (1 μM), DMS (10 μM) or FTY720 (1 μM) and then subjected to incubat
with anti-PDGFR-β antibody and revealed for anti-phosphotyrosine. The blot was
methods. (B) HSCs were incubated in the absence (lanes 1, 3 and 5) or presence (lanes
the whole lysate was subjected to Western blot analysis for S1P1 and PDGF
immunoprecipitation with anti-PDGFR-β (lanes 3 and 4) and anti-S1P1 (lanes 5 and
blots were reprobed with anti-PDGFR-β and anti-S1P1, respectively. (C) Cells were
1 μM), incubated with PDGF-BB (10 ng/ml) for 10 min, subsequently subjected to S
ERK and Akt, with antibody anti-phospho-ERK (Thr202/Tyr204) and anti-phospho
(arbitrary units) of phospho-ERK and phospho-Akt bands expressed as mean±SD. T
figure represents four separate experiments. (D) Cells were pretreated for 20 min with
6) and FTY720 (1 μM, lanes 5 and 6), and then subjected to incubation with PDGF
analyzed byWestern blot for the presence of activated forms of ERK and Akt, with an
bar graph represents the values of a densitometric analysis (arbitrary units) of phosp
four separate experiments. Compared with the effect of PDGF-BB, changes due to pre
(Pb0.05 or higher degree of significance). Compared with the effect PDGF-BB in
significant (PN0.05). (E) Effect of FTY720 on activation of ERK and Akt in HSCs tra
with PDGF-BB (10 ng/ml) alone or in the presence of FTY720 (1 μM) for 24 h. S
phospho-ERK (Thr202/Tyr204) and anti-phospho-Akt (Ser473). The bar graph repres
phospho-Akt bands expressed as mean±SD. The figure represents four separate expe
were statistically significant (Pb0.01 or higher degree of significance). Compared
siRNA were not statistically significant (PN0.05).3.2. FTY720 induces S1P1 rapid internalisation
To demonstrate the partial involvement of S1PRs in
mediating FTY720 action, we evaluated the expression level
of different S1PRs by Western blotting.
As shown in Fig. 4A, S1P1 and S1P2 was detected in HSCs,
but not S1P3 and S1P4 (data not shown), probably due to the
low protein expression in these cells. S1P1 expression increases
after only 8 days HSC culture and on the third passage (Fig. 4A,
lanes 1–3). Stimulation of HSCs subjected to the third passage
by PDGF and S1P for 24 h does not seem to affect its expression
(Fig. 4A, lanes 3–5).
We observed a decrease in S1P1 expression after FTY720
treatment on cultured activated HSCs for 24 h (Fig. 4A, lanes 3
and 6). This result is consistent with the assumption that
FTY720, binding with high affinity to S1P1 but not to S1P2,
induces early internalisation of the receptor, blocking normal
S1P signal pathways [42].
The decreased membrane location of S1P1 was showed by
Western blot quantitation, performed on different subcellular
compartments from the post-nuclear fraction of HSCs separated
by optiprep gradient and subjected to several incubations.
A 70% decrease in S1P1 was evidenced in membrane
fractions after FTY720 treatment (Fig. 4C vs B), supporting the
hypothesis of the potential role of this drug in the S1P1
internalization. On the other hand, DMS did not affect the level
of the receptor at the plasma membranes (Fig. 4E vs C) in HSCs
treated with FTY720. These findings would seem to be in
agreement with previous data obtained on T-lymphocytes,
which showed internalisation of S1P1 upon FTY720 treatment
without receptor activation but favoring the degradation
pathway by blocking receptor recycling [29].
3.3. Effect of FTY720 on HSC migration
To evaluate the effect of FTY720 on cell motility, two
different experimental approaches were used: the wound-nd Akt activation. (A) Cells were pretreated for 20 min with, PTX (100 ng/ml),
ion with PDGF-BB (10 ng/ml) for 10 min. Cells were then immunoprecipitated
reprobed with anti-PDGFR antibody as described in the section Materials and
2, 4 and 6) of PDGF-BB (10 ng/ml) for 10 min; an aliquot corresponding to ¼ of
R-β, respectively (lanes 1 and 2); the remainder of the lysate underwent
6) antibodies and revealed for anti-S1P1 and anti-PDGF-βR, respectively. The
pretreated for 20 min with increasing concentrations of FTY720 (0.1, 0.5 and
DS-PAGE and analyzed by Western blot for the presence of activated forms of
-Akt (Ser473). The bar graph represents the values of a densitometric analysis
he blots were reprobed with anti-ERK and anti-Akt antibodies, respectively. The
PTX (100 ng/ml, lane 2), VPC23019 (1 μM, lane 3), DMS (10 μM, lanes 4 and
-BB (10 ng/ml) for 10 min. Finally samples were subjected to SDS-PAGE and
tibody anti-phospho-ERK (Thr202/Tyr204) and anti-phospho-Akt (Ser473). The
ho-ERK and phospho-Akt bands expressed as mean±SD. The figure represents
treatment with PTX or VPC23019, DMS or FTY720 were statistically significant
association with FTY720, changes due to DMS treatment were not statistically
nsfected with control siRNA or SphK2 siRNA for 48 h, and subsequently treated
amples were subjected to SDS-PAGE and analyzed by Western blot with anti-
ents the values of a densitometric analysis (arbitrary units) of phospho-ERK and
riments. Compared with the effect of PDGF-BB, changes due to SphK2 siRNA
with the effect PDGF-BB in association with FTY720, changes due to SphK2
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modified Boyden chamber system. Fig. 5A shows a wounded
monolayer incubated in medium containing PDGF-BB alone or
in association with increasing doses of FTY720.
PDGF-BB induced cell migration, leading to wound closure
within 24 h after injury. In the presence of FTY720, PDGF-
induced cell migration in the wounded area was inhibited in a
concentration-dependent manner. The level of inhibition,
measured as a percentage of the whole wound length, was
65% and 90% studied in response to 0.3 and 1 μM of FTY720,
respectively.
Evaluation of chemotaxis in a modified Boyden chamber
system (Fig. 5B) confirmed the 50% decrease in cell migration
when cells, stimulated by PDGF, were pretreated with PTX,
VPC23019 and DMS.
The greater inhibitory effect of FTY720 compared to that
resulting from treatment with PTX or VPC23019, underlines
the fact that, as in cell proliferation, the drug exerts its action
through different targets.
Furthermore, the FTY720 inhibitory effect is neither totally
removed by DMS pretreatment (Fig. 5B, right panel), nor by
siRNA to SphK2 (Fig. 5C), supporting the concept that, even
for chemotaxis, phosphorylated FTY720 may not be the only
active form of the compound.
3.4. FTY720 inhibition on signalling events
To examine the intracellular mechanisms underlying the
action of FTY720 on PDGF-induced cell proliferation and
migration, we first analyzed FTY720 effects on PDGF receptor-
β (PDGFR-β) phosphorylation. HSCs were pretreated for
20 min with increasing concentrations of FTY720 and then
subjected to PDGF-BB (10 ng/ml) for 10 min.
As shown in Fig. 6A, FTY720 treatment resulted in a
marked decrease in PDGFR-β tyrosine phosphorylation (Fig.
6A, lane 6).
To establish whether this effect was mediated by inhibition
of the S1P signalling pathway we observed that PTX or
VPC23019 treatment did not affect PDGFR-β phosphorylation,
as revealed by anti-P-Tyr immunoblotting (Fig. 6A lanes 3 and
4). On the other hand, the decrease in PDGFR-β phosphoryla-
tion brought about by FTY720 was not reversed by DMS
pretreatment (Fig. 6B).
These data led us to hypothesize that the FTY720 inhibitory
effect on receptor tyrosine phosphorylation may be due to direct
interaction between the drug and PDGFR-β, and not to the
phosphorylation state of FTY720.
Notably, we did not observe a physical interaction between
PDGFR-β and S1P1, as revealed by Western blot with anti-
PDGFR-β and anti-S1P1 on anti-S1P1 and anti-PDGFR-β
immunoprecipitates, respectively (Fig. 6B).
We also studied the effect of FTY720 on the pathways
downstream of PDGFR-β, particularly phosphatidylinositol-3-
kinase (PI3K) and extracellular regulated kinase 1 and 2 (ERK1/
2) signalling pathways, because they have already been shown to
play a central role in PDGF-induced proliferation and migration
of HSCs during the progression of liver fibrosis [43,44].We evaluated the activation state of Akt and ERK1/2, key
molecules of the PI3K and ERK pathways, on total HSC
lysates, pretreated for 20 min with increasing concentrations of
FTY720 and then subjected to PDGF-BB (10 ng/ml) for 10 min.
ERK1/2 and Akt phosphorylation was inhibited proportionally
to the increasing concentrations of FTY720 (Fig. 6C).
In addition, since the phosphorylation of ERK1/2 and Akt in
PDGF-stimulated HSCs proved to be more remarkably
decreased in the presence of FTY720 (Fig. 6C), as compared
with the effect observed in samples treated with PTX or,
alternatively, VPC23019 (Fig. 6D, lanes 2, 3, and 5), it is
assumed that FTY720 exploits S1PR-independent signalling
pathways. Besides, the treatment of DMS or siRNA to SphK2
had no statistically significant effect (PN0.05) on the reversal of
the inhibitory effect of FTY720 on ERK1/2 and Akt
phosphorylation. (Fig. 6D, lanes 4–6; Fig. 6E).
3.5. FTY720 effects on PDGF-BB induced α-SMA expression
During HSC activation, PDGF increased the expression of
α-SMA protein, a molecular marker for the contractile
phenotype, allowing cellular migration to the site of liver injury
[45]. As expected [46], S1P promoted prompt expression of α-
SMA, and this effect was partially accumulative on that
observed after PDGF-BB stimulation (Fig. 7A). α-SMA
expression was also dose-dependently reduced by FTY720 in
PDGF-stimulated HSCs (Fig. 7B).
The results shown in Fig. 8 indicate that treatment of PDGF-
BB-stimulated HSCs with either PTX or VPC23019 inhibited
α-SMA expression, suggesting that the action of PDGF-BB,
also in this case, is partly mediated by S1PRs. The main
inhibitory effect of FTY720 on α-SMA expression in the same
experimental conditions strengthens our hypothesis that
FTY720 recognizes targets other than S1PRs. Pretreatment
with DMS and down-regulation of Spkh2 by siRNA are capable
of partially restoring α-SMA expression in the presence of
FTY720 in PDGF-BB stimulated HSCs, supporting the concept
that FTY720 may be active also independently of its
phosphorylation.
4. Discussion
HSCs play a pivotal role in the development of liver fibrosis,
acquiring, upon liver injury, an activated phenotype, including
proliferation, migration and increased expression and release of
ECM proteins in the Disse space. Therefore, blocking HSC
activation is considered an emerging area in the search for
antifibrotic drugs.
PDGF-BB has been shown to be a key molecule in HSC
activation, increasing mitogenesis, stimulating chemotaxis, and
affecting the transcription of several genes [6–9]. Since it has
been demonstrated in several cell types that cross-talk between
PDGF and S1P signalling pathways occurs, we investigated the
occurrence and potential role of this interplay in HSC
activation.
We first established the presence of S1PRs in HSCs, particu-
larly of S1P1, following activation of which cell proliferation
Fig. 7. Effect of PTX, VPC23019, DMS and FTY720 on expression of α-SMA. (A) HSCs were incubated for 24 h in OPTIMEM medium, pretreated with PTX
(100 ng/ml) for 16 h, or with VPC23019 (1 μM) for 1 h, followed by stimulation with PDGF-BB (10 ng/ml), S1P (1 μM), or FTY720 (1 μM) in the presence of PDGF,
respectively, for 24 h. Compared with the effect of PDGF-BB, S1P, S1P in association with PDGF-BB, all considered alone, changes, due to pretreatment with PTX or
VPC23019, were statistically significant (Pb0.05 or higher degree of significance); pretreatment with PTX or VPC23019 did not result in statistically significant
changes compared to control treated with FTY720 in association with PDGF-BB alone. (B) Cells were pretreated with DMS (10 μM) for 30 min and subsequently for
24 h with PDGF (10 ng/ml) alone or in the presence of FTY720 (1 μM). Compared with the effect of PDGF-BB or FTY720 in association with PDGF-BB, changes due
to pretreatment with DMSwere statistically significant (Pb0.05 or higher degree of significance); also statistically significant was the difference between HSCs treated
with DMS and PDGF-BB alone or in the presence of FTY720. (C) Expression of α-SMA after treatment with SphK2 siRNA, as described in the section Materials and
methods. Compared with the effect of PDGF-BB or FTY720 in association with PDGF-BB, changes due to SphK2 siRNAwere statistically significant (Pb0.05 or
higher degree of significance). The bar graph represents the values of a densitometric analysis (arbitrary units) of α-SMA bands expressed as mean±SD. The blots
were reprobed with anti-GADPH antibody as loading control. The figure represents four separate experiments.
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(PTX and VPC23019), we assessed the partial inhibition of
the effects mediated by PDGF signalling, i.e., cell prolife-
ration and migration, α-SMA expression, ERK1/2 and Akt
phosphorylation.
The interplay between these two signalling pathways does
not occur through a physical interaction between PDGFR-β and
S1P1, as evidenced by co-immunoprecipitation, but through theinvolvement of a SphK activity. In fact, with DMS, an inhibitor
of SphKs, we obtained effects similar to those observed with
PTX and VPC23019, suggesting that modulators of the S1P
pathway may antagonise the PDGF signalling pathway, and
thereby act as potential antifibrotic agents.
To explore this possibility, we studied the effects of
FTY720, whose phosphorylated form acts as a S1PR
modulator [21], on HSCs, observing a reduced response to
358 A.M. Brunati et al. / Biochimica et Biophysica Acta 1783 (2008) 347–359PDGF activation in a concentration range between 0.1 to
1 μM, which was not related to cytotoxicity or apoptosis for
primary HSCs. In contrast to PTX and VPC23019, FTY720
turned out to be more effective in inhibiting proliferation and
migration of PDGF-activated HSCs, probably acting by an
alternative mechanism. In fact, increasing concentrations of
S1P, used as an activator of HSCs, competitively removed the
inhibitory effect of VPC23019, but not responsiveness to
FTY720 treatment.
In this respect, DMS and siRNA against SphK2, enzyme
responsible for FTY720 phosphorylation and reported to be the
more common isoform of SphKs in the liver, reduced but not
completely reversed the inhibitory effect of this compound,
mainly on cell proliferation and cell migration.
While investigating various conditions promoting FTY720
phosphorylation, we found that triggering of PDGFR-β
increased this event, which in turn proved to be inhibited by
siRNA to SphK2: this finding seems to underline that PDGF
signalling mediates SphK2 activation. Even though the under-
standing of the mechanisms underlying SphK2 regulation have
not been deepened, this may be the second example of agonist-
dependent regulation of SphK2 by growth factors, as recently
reported for EGF [47].
Although earlier studies have emphasized that FTY720 is
rapidly converted to FTY720-P in vivo , thus exhibiting higher
affinity for S1PRs and modulating S1P signalling, our data
demonstrate that this phosphorylation event may not account for
all the effects observed in our cellular model. In fact, the
decrease in the level of S1P1 on the plasma membrane, which
was not reversed by DMS, appears to be independent of FTY720
phosphorylation and might not exclude an interaction, albeit at a
low affinity [48], between nonphosphorylated FTY720 and
S1PRs. Moreover, the level of tyrosine phosphorylation of
PDGFR-β is altered by FTY720 and not reversed by DMS
treatment, remaining substantially unchanged after blockage of
S1P signalling by PTX and VPC23019, supporting the
hypothesis that FTY720 may act by several mechanisms of
action.
Emerging evidence are in agreement with our results
indicating that FTY720 is capable of interacting with various
targets, thus affecting several cellular processes. It has been
shown to inhibit cPLA2, with significant implications for the
potential therapeutic mechanism of action of FTY720 in
eicosanoid-driven inflammatory disorders [49] and to induce
extracellular barrier enhancement, providing insights into the
processes underlying pulmonary vascular permeability through
a potential S1P1-independent mechanism that involves an
alternative Gi-coupled receptor [50]. In different solid tumor
and multiple myeloma cell lines, the proapoptotic effects of
FTY720 has been described not to require FTY720 phosphor-
ylation , albeit at high micromolar levels (z10 μM) through a
S1PR-independent, ceramide-dependent apoptotic pathway
[51]. It has also been considered as a novel therapeutic approach
for patients with imatinib/dasatinib-sensitive and -resistant
advanced chronic myelogenous leukemia and Philadelphia
chromosome-positive acute lymphocytic leukemia via activa-
tion of PP2A, requiring neither SphK-dependent FTY720 phos-phorylation nor triggering of Gi protein-coupled S1PR-mediated
signalling [52].
In summary, FTY720 displays the ability to suppress cell
proliferation and migration in virtue of its pleiotropicity of
effects, by interfering with the S1P and PDGF signalling
pathways on cultured HSCs; underscoring that this compound,
already in Phase III clinical trials for multiple sclerosis and solid
organ transplantation, might also be evaluated in further in vivo
studies on human inflammatory diseases, particularly liver
fibrosis.
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